Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5665908 | Diagnostic Microbiology and Infectious Disease | 2017 | 6 Pages |
â¢HCV core antigen highly correlates with HCV RNA levels.â¢HCV core antigen is useful for the diagnosis of candidates to antiviral therapy.â¢HCV core antigen may be used for tailoring response to DAAs outside clinical trials.â¢An algorithm including HCV core antigen may simplify patient management.
We evaluated the utility of Architect core antigen assay® Abbott Diagnostics (HCVAg) for monitoring patients with HCV infection and compared to HCV-RNA quantification (Cobas Ampliprep TaqMan-Roche Diagnostics). Samples from 262 patients were studied. Mean baseline HCV RNA and HCVAg levels were similar for responders (6.2 log IU/mL and 3.4 log fmol/L) and non-responders (6.1 log IU/mL and 3.2 log fmol/L), respectively. Only 10 patients failed to achieve SVR12 and all were detected by both assays. To evaluate HCVAg quantification as a tool for the detection of failure to DAAs, we performed a retrospective study of 132 non-responder patients. Mean HCV RNA and HCVAg levels at the time of detection of therapeutic failure were 5.88 ± 0.97 log IU/mL and 3.19 ± 0.79 log fmol/L, respectively. HCVAg (>3 fmol/L) was detected in 130/132 patients (98.5%). HCVAg assay was useful for patient selection and for evaluating virological response to DAAs in the real world.